Luye Pharma Group Stock price
Compare with Peer Group
Is Luye Pharma Group a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Luye Pharma Group Stock Analysis
Analyst Opinions
8 Analysts have issued a Luye Pharma Group forecast:
Analyst Opinions
8 Analysts have issued a Luye Pharma Group forecast:
Don't miss a Thing! We will send you all news about Luye Pharma Group directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. The company employs 5,221 full-time employees The company went IPO on 2014-07-09. The firm operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.
| Head office | Bermuda |
| CEO | Mr. Liu |
| Employees | 5,221 |
| Website | www.luye.cn |


